A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

This is an interventional prevention trial for Influenza A focused on measuring Flu Read More

Inclusion Criteria:

• Participant must be 18 to < 65 years of age, at time of randomization
• Participants must be in good health, determined from medical history and no clinically significant findings from physical examination, 12-lead electrocardiogram (ECG), vital signs, and laboratory values

Exclusion Criteria:

• History or clinical evidence of conditions considered high risk for developing influenza-related complications
• History of confirmed influenza infection within 3 months prior to randomization.
• Febrile illness with or without respiratory symptoms
• History of malignancy within 5 years or participant is under evaluation for malignancy.
• Any condition or receipt of any medication contraindicating IM injection, as judged by the investigator.
• History of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis
• Participant has a clinically significant medical condition, physical exam finding, or abnormal laboratory result.
• Prior or planned receipt of any influenza vaccine for the upcoming season.
• Received any investigational agent within 90 days or within 5 half-lives of the investigational agent.